{
    "clinical_study": {
        "@rank": "97610", 
        "acronym": "FOrMAT", 
        "arm_group": {
            "arm_group_label": "Targeted genetic sequencing of tumour specimen"
        }, 
        "biospec_descr": {
            "textblock": "Both fresh frozen tissue and formalin-fixed paraffin-embedded (FFPE) tumour samples will be\n      obtained.\n\n      Biopsies may be taken at entry to the study and/or at the time of radiological response\n      assessment. Each patient can have a maximum of 3 research biopsies in this study.\n\n      Up to 35 ml of blood  will be collected at study entry to provide normal germline DNA and\n      for possible additional biomarker analysis. If the patient has consented to optional blood\n      sample collection, then additional blood samples will also be collected at the time of\n      radiological response assessment to study molecular changes that occur during treatment."
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "This study will assess the feasibility of sequencing locally advanced/metastatic\n      gastrointestinal cancers in real-time to enable future treatment stratification by molecular\n      characteristics. Targeted next generation sequencing of a panel of genes will be performed\n      on tumour specimens and results will be discussed at a Sequencing Tumour Board to establish\n      if a patient is potentially suitable for a targeted therapy."
        }, 
        "brief_title": "Feasibility of a Molecular Characterisation Approach to Treatment", 
        "condition": "Advanced Gastrointestinal Cancers", 
        "condition_browse": {
            "mesh_term": "Gastrointestinal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Locally advanced or metastatic gastrointestinal cancer (including oesophageal,\n             oesophagogastric junction, gastric, pancreatic, biliary and colorectal cancers).\n\n          2. Histological or cytological confirmation of diagnosis of malignancy.\n\n          3. Patients must either:\n\n               1. Have received at least one line of treatment for locally advanced/metastatic\n                  disease OR\n\n               2. Be about to start/currently undergoing their first line of treatment for locally\n                  advanced/metastatic disease\n\n          4. 18 years of age and over .\n\n          5. Performance status less than or equal to 2.\n\n          6. Able to provide fully informed consent.\n\n          7. Patients must either:\n\n               1. Have an available tumour specimen (FFPE or fresh frozen) from either the primary\n                  tumour or a metastasis. Metastatic samples may be from any site with the\n                  exception of bone. OR\n\n               2. Have a site of disease which is amendable to biopsy\n\n        Exclusion Criteria:\n\n          -  There are no specific exclusion criteria for this study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Locally advanced or metastatic gastrointestinal cancer (including gastroesophageal,\n        pancreatic, biliary tract and colorectal cancer)"
            }
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 31, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02112357", 
            "org_study_id": "CCR 3994"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "molecular profiling", 
            "genetic sequencing", 
            "personalised medicine", 
            "gastrointestinal cancer"
        ], 
        "lastchanged_date": "April 16, 2014", 
        "location": {
            "contact": {
                "email": "annie.woodburne@rmh.nhs.uk", 
                "last_name": "Annie Woodburne, MSc, BSc", 
                "phone": "+44 (0)208 661 3807"
            }, 
            "facility": {
                "address": {
                    "city": "London and Surrey", 
                    "country": "United Kingdom", 
                    "zip": "SM 25PT"
                }, 
                "name": "The Royal Marsden NHS Foundation Trust"
            }, 
            "investigator": [
                {
                    "last_name": "Dr. Naureen Starling, BSc, MBBS, MRCP", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Dr. Sing Yu Moorcraft, MB BCh, MRCP", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_groups": "1", 
        "official_title": "FOrMAT - Feasibility of a Molecular Characterisation Approach to Treatment", 
        "other_outcome": [
            {
                "measure": "Response rate for patients who received a targeted treatment as a result of genetic sequencing.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Overall survival of patients who received targeted treatment.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "To examine tumour heterogeneity in patients with paired specimens", 
                "measure": "Evaluation of any changes in molecular markers at the time of disease progression or response to those from previous specimens.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Description of the microRNA expression profile of gastrointestinal tumours", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Evaluation of any changes in circulating tumour DNA at the time of progression or response in comparison to previous specimens", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "Duration of response for patients who received a targeted treatment as a result of genetic sequencing.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "overall_contact": {
            "email": "naureen.starling@rmh.nhs.uk", 
            "last_name": "Dr. Naureen Starling, BSc, MBBS, MRCP", 
            "phone": "+44 (0)208 661 3156"
        }, 
        "overall_contact_backup": {
            "email": "annie.woodburne@rmh.nhs.uk", 
            "last_name": "Annie Woodburne, BSc, MSc", 
            "phone": "+44 (0)208 661 3807"
        }, 
        "overall_official": {
            "affiliation": "The Royal Marsden NHS Foundation Trust", 
            "last_name": "Dr. Naureen Starling, BSc, MBBS, MRCP", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "England: Sponsor- The Royal Marsden NHS Foundation Trust", 
                "England: Ethics Committee NRES Committee London - Stanmore"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The percentage of patients in whom a currently actionable molecular alteration was detected by genetic sequencing.", 
            "safety_issue": "No", 
            "time_frame": "18 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02112357"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "The concordance of results obtained from genetic sequencing compared to standard clinically validated techniques.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "The proportion of patients in whom genetic sequencing was successfully performed.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "To assess the potential impact of genetic sequencing results on patients' treatment", 
                "measure": "The percentage of patients with a currently actionable genetic alteration who received targeted therapy as a result of genetic sequencing.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "description": "To assess whether genetic sequencing results can be obtained within a clinically meaningful timeframe", 
                "measure": "Evaluation of the time required to obtain genetic sequencing results to see if genetic sequencing could be practically incorporated into clinical practice.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "The proportion of screened patients who decide to participate in the trial and their reasons for participation or deciding not to participate.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "The concordance of results obtained from core biopsy versus fine needle aspirate specimens from individual patients.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }, 
            {
                "measure": "The number needed to enroll into the trial to identify one patient with a targetable genetic alteration and the number needed to enroll into the trial to treat one patient with a targeted agent.", 
                "safety_issue": "No", 
                "time_frame": "18 months"
            }
        ], 
        "source": "Royal Marsden NHS Foundation Trust", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Royal Marsden NHS Foundation Trust", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "April 2014"
    }
}